Lupin Ltd. NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1972.40 13.10 (0.67%)

547.6K

NSE+BSE Volume

NSE 13 Oct, 2025 3:31 PM (IST)

US FDA Approval

Lupin's facility in New Jersey, US, receives Form 483 with one observation from the US FDA See details

Lupin Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Lupin Ltd. from all sources in a single place.

Load latest

02 Apr 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company, has acquired the entire share capital of Renascience Pharma Limited, United Kingdom.

31 Mar 2025

1972.40

0.67%

Lupin Board Okays Transfer Of API R&D Division To Arm

NDTV Profit

The company had on Feb. 12 intimated regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.

Lupin Ltd. is trading below its 150 day SMA of 1979.6

31 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Restructuring

BSE India

Modification to the slump sale transaction of transfer of the Over-the-Counter Consumer Healthcare Business.

31 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Restructuring

BSE India

Transfer of Company''s API R&D Division to Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company on slump sale basis.

31 Mar 2025

1972.40

0.67%

Corp. Note

Lupin Ltd - 500257 - Board Meeting Outcome for Outcome Of The Board Meeting Held On …

BSE India

Outcome of the Board Meeting held on March 31, 2025.

28 Mar 2025

1972.40

0.67%

SAST

Lupin Ltd - 500257 - Closure of Trading Window

BSE India

Intimation regarding closure of trading window.

28 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Retirement of Senior Management Personnel(s).

22 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Digital Health Introduces Comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology.

21 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery.

21 Mar 2025

1972.40

0.67%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Intimation regarding allotment of 24101 shares under ESOP.

Is Lupin Ltd. worth buying?

926 Votes:

Buy 72.79%

Sell 17.49%

Hold 9.72%

RESEARCH REPORTS

Buy SEE REPORTS >

Hold SEE REPORTS >